Ranibizumab

Ranibizumab
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	Vascular endothelial growth factor A (VEGF-A)
Clinical data
Trade names	Lucentis, others
Biosimilars	Byooviz, Cimerli, Epruvy, Ranivisio, Raniviz, Ranopto, Rimmyrah, Susvimo, Ximluci ranibizumab-eqrn, ranibizumab-nuna
AHFS/Drugs.com	Monograph
MedlinePlus	a607044
License data	US DailyMed: Ranibizumab;
Pregnancy; category	AU: D;
Routes of; administration	Intravitreal injection
ATC code	S01LA04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	Approx. 9 days
Identifiers
CAS Number	347396-82-1 ;
DrugBank	DB01270 ;
ChemSpider	none;
UNII	ZL1R02VT79;
KEGG	D05697 ;
ChEMBL	ChEMBL1201825 ;
Chemical and physical data
Formula	C2158H3282N562O681S12
Molar mass	48379.97 g·mol−1
	(what is this?) (verify)

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006, and in the European Union in January 2007.